Cisplatin Preferentially Binds Mitochondrial DNA and Voltage-Dependent Anion Channel Protein in the Mitochondrial Membrane of Head and Neck Squamous Cell Carcinoma: Possible Role in Apoptosis

Purpose: Cisplatin adducts to nuclear DNA (nDNA) are felt to be the molecular lesions that trigger apoptosis, but the mechanism linking nDNA adduct formation and cell death is unclear. Some literature in the last decade has suggested a possible direct effect of cisplatin on mitochondria independent of nDNA interaction. In this study, we define separately the sequelae of cisplatin interactions with nDNA and with mitochondria in head and neck squamous cell carcinoma (HNSCC) cell lines. Experimental Design: Cisplatin binding to mitochondrial DNA (mtDNA) and proteins was analyzed by atomic absorption spectroscopy and other methods. Results: Following 1 hour of exposure to cisplatin, platinum adducts to mtDNA were 300- to 500-fold more abundant than adducts to nDNA; these differences were not due to differences in rates of adduct repair. Whereas HNSCC cell cytoplasts free of nDNA retained the same dose-dependent cisplatin sensitivity as parental cells, HNSCC ρ0 cells free of mtDNA were 4- to 5-fold more resistant to cisplatin than parental cells. Isolated mitochondria released cytochrome c within minutes of exposure to cisplatin, and ultrastructural analysis of intact HNSCC cells by electron microscopy showed marked mitochondrial disruption after 4 hours of cisplatin treatment, whereas the nucleus and other cellular structures remain intact. The very prompt release of cytochrome c from isolated mitochondria implies that apoptosis does not require alteration in mitochondrial gene transcription. Further, cisplatin binds preferentially to mitochondrial membrane proteins, particularly the voltage-dependent anion channel. Conclusions: Cisplatin binding to nDNA is not necessary for induction of apoptosis in HNSCC, which can result from direct action of cisplatin on mitochondria.

[1]  Jérôme Kluza,et al.  Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D. , 2006, Cancer research.

[2]  H. Yamaguchi,et al.  Arsenic trioxide (As2O3) induces apoptosis through activation of Bax in hematopoietic cells , 2005, Oncogene.

[3]  R. Rotem,et al.  Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. , 2005, Cancer research.

[4]  C. Frezza,et al.  4-hydroxymethyl-1,6,8-trimethylfuro[2,3-h]quinolin-2(1H)-one induces mitochondrial dysfunction and apoptosis upon its intracellular oxidation. , 2005, Journal of medicinal chemistry.

[5]  Shaomeng Wang,et al.  (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. , 2005, Molecular cancer therapeutics.

[6]  G. Babcock,et al.  Unconjugated bilirubin induces apoptosis in colon cancer cells by triggering mitochondrial depolarization , 2004, International journal of cancer.

[7]  R. D. De Abreu,et al.  Bcl-2 prevents loss of mitochondria in CCCP-induced apoptosis. , 2004, Experimental cell research.

[8]  G. Kroemer,et al.  Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA , 2004, Oncogene.

[9]  R. Perez,et al.  The effects of ethidium bromide induced loss of mitochondrial DNA on mitochondrial phenotype and ultrastructure in a human leukemia T-cell line (MOLT-4 cells). , 2004, Toxicology and applied pharmacology.

[10]  G. Smoorenburg,et al.  Ultrastructural changes in the albino guinea pig cochlea at different survival times following cessation of 8-day cisplatin administration , 2004, Acta oto-laryngologica.

[11]  I. Chang,et al.  Resistance of Mitochondrial DNA-depleted Cells against Cell Death , 2004, Journal of Biological Chemistry.

[12]  V. De Pinto,et al.  VDAC1 Is a Transplasma Membrane NADH-Ferricyanide Reductase* , 2004, Journal of Biological Chemistry.

[13]  Taesoo Kim,et al.  Induction of the mitochondrial permeability transition by selenium compounds mediated by oxidation of the protein thiol groups and generation of the superoxide. , 2003, Biochemical pharmacology.

[14]  N. Davies,et al.  Chemotherapy induced gastrointestinal toxicity in rats: involvement of mitochondrial DNA, gastrointestinal permeability and cyclooxygenase -2. , 2003, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[15]  H. Itoh,et al.  P53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. , 2003, Cancer research.

[16]  S. Y. Cajal,et al.  Role of the p38 MAPK pathway in cisplatin-based therapy , 2003, Oncogene.

[17]  S. Silbernagl,et al.  Inhibition of mitochondria prevents cell death in kidney epithelial cells by intra- and extracellular acidification. , 2003, Kidney international.

[18]  Johan Hansson,et al.  Cisplatin Induces Endoplasmic Reticulum Stress and Nucleus-independent Apoptotic Signaling* , 2003, The Journal of Biological Chemistry.

[19]  J. Perez,et al.  Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. , 2003, Current medicinal chemistry.

[20]  C. Rudin,et al.  Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. , 2003, Cancer research.

[21]  P. Devarajan,et al.  Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways , 2002, Hearing Research.

[22]  J. Schellens,et al.  DNA-based drug interactions of cisplatin. , 2002, Cancer treatment reviews.

[23]  G. Amuthan,et al.  Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells , 2002, Oncogene.

[24]  David Polsky,et al.  Focus on melanoma. , 2002, Cancer cell.

[25]  H. You,et al.  Rac1 prevents cisplatin‐induced apoptosis through down‐regulation of p38 activation in NIH3T3 cells , 2002, FEBS letters.

[26]  P. Devarajan,et al.  Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. , 2002, Journal of the American Society of Nephrology : JASN.

[27]  S. Isonishi,et al.  Mitochondria in platinum resistant cells. , 2001, Human cell.

[28]  G. Singh,et al.  Mitochondrial contributions to cancer cell physiology: potential for drug development. , 2001, Advanced drug delivery reviews.

[29]  J. Essigmann,et al.  Mechanisms of resistance to cisplatin. , 2001, Mutation research.

[30]  José Perez,et al.  Is cisplatin-induced cell death always produced by apoptosis? , 2001, Molecular pharmacology.

[31]  Christian Renken,et al.  Preservation of Mitochondrial Structure and Function after Bid- or Bax-Mediated Cytochrome c Release , 2000, The Journal of cell biology.

[32]  G. Kroemer,et al.  Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis , 2000, Oncogene.

[33]  B. Joseph,et al.  The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. , 1999, Cancer research.

[34]  Dean P. Jones,et al.  Cytochrome c-mediated Apoptosis in Cells Lacking Mitochondrial DNA , 1999, The Journal of Biological Chemistry.

[35]  D. Green,et al.  Caspases Induce Cytochrome c Release from Mitochondria by Activating Cytosolic Factors* , 1999, The Journal of Biological Chemistry.

[36]  B. Liang,et al.  Increased sensitivity to cis-diamminedichloroplatinum induced apoptosis with mitochondrial DNA depletion , 1998, Cell Death and Differentiation.

[37]  M. Anderson,et al.  Glutathione: an overview of biosynthesis and modulation. , 1998, Chemico-biological interactions.

[38]  N. Kaplowitz,et al.  Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol‐treated rats: Effect of membrane physical properties and S‐adenosyl‐L‐methionine , 1997, Hepatology.

[39]  N. Kaplowitz,et al.  GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. , 1997, The American journal of physiology.

[40]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[41]  J. Fagerberg,et al.  Pharmacokinetics of cisplatin and its monohydrated complex in humans. , 1996, Journal of pharmaceutical sciences.

[42]  N. Kaplowitz,et al.  Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes. , 1995, Molecular pharmacology.

[43]  M. Poirier,et al.  Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. , 1995, Mutation research.

[44]  M. Raff,et al.  Programmed cell death and Bcl‐2 protection in the absence of a nucleus. , 1994, The EMBO journal.

[45]  John Calvin Reed,et al.  Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA , 1993, Nature.

[46]  P. Andrews,et al.  Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. , 1992, Cancer research.

[47]  P. Andrews,et al.  Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance. , 1992, Cancer research.

[48]  A. Meister,et al.  Inhibition of glutathione synthesis in the newborn rat: a model for endogenously produced oxidative stress. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[49]  A. Pa,et al.  Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. , 1990 .

[50]  M. King,et al.  Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. , 1989, Science.

[51]  K. Tamura,et al.  Rapid isolation method of animal mitochondrial DNA by the alkaline lysis procedure , 1988, Biochemical Genetics.

[52]  C. Sorenson,et al.  Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. , 1988, Cancer research.

[53]  A. Meister,et al.  Origin and turnover of mitochondrial glutathione. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[54]  F. Tietze Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. , 1969, Analytical biochemistry.

[55]  G. Singh,et al.  Evidence for lack of mitochondrial DNA repair followingcis-dichlorodiammineplatinum treatment , 2008, Cancer Chemotherapy and Pharmacology.

[56]  H. Mouridsen,et al.  Discussion at the Satellite symposium: Ifosfamide in gynecological tumors , 2004, Cancer Chemotherapy and Pharmacology.

[57]  K. Tew,et al.  Cellular thiols and reactive oxygen species in drug-induced apoptosis. , 2001, The Journal of pharmacology and experimental therapeutics.

[58]  P. Andrews,et al.  Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines , 2000, Cancer Chemotherapy and Pharmacology.

[59]  M. King,et al.  Isolation of human cell lines lacking mitochondrial DNA. , 1996, Methods in enzymology.

[60]  A. Eastman,et al.  The origins of DNA breaks: a consequence of DNA damage, DNA repair, or apoptosis? , 1992, Cancer investigation.

[61]  H. Bier Circumvention of drug resistance in cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79 in vitro and in vivo. , 1991, Acta oto-laryngologica.

[62]  T. Murata,et al.  Preferential binding of cisplatin to mitochondrial DNA and suppression of ATP generation in human malignant melanoma cells. , 1990, Biochemistry international.

[63]  S. Howell,et al.  Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. , 1990, Cancer cells.

[64]  A. Eastman Activation of programmed cell death by anticancer agents: cisplatin as a model system. , 1990, Cancer cells.

[65]  A. Meister,et al.  Mitochondrial damage in muscle occurs after marked depletion of glutathione and is prevented by giving glutathione monoester. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[66]  S. Howell,et al.  Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. , 1988, Chemico-biological interactions.

[67]  J. Kovach,et al.  Pharmacokinetics of anticancer agents in humans , 1983 .

[68]  A. Prestayko 21 – CLINICAL PHARMACOLOGY OF CISPLATIN , 1981 .